NCT02624960WithdrawnNot Applicable
Safety and Performance of the AccuCinch® Ventricular Repair System
Conditions
Interventions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Withdrawn
- Sponsor
- Ancora Heart, Inc.
- Primary Endpoint
- The additive reduction in the mitral annular axial dimensions (anteroposterior plus commissure-to-commissure axes) measured via echocardiography, paired by subject
Study Overview
Brief Summary
This is a single-arm, multi-center, open-label controlled study that will assess the safety and performance of the Accucinch System to induce left ventricular reverse remodeling and reduce the severity of functional mitral regurgitation in symptomatic adult patients with mitral regurgitation and left ventricular remodeling due to dilated cardiomyopathy (ischemic or non-ischemic etiology), who are of high operative risk.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Study patient is an adult of legal consent age
- •Severity of FMR: ≥ Moderate
- •Ejection Fraction: ≥20 to ≤60%
- •Symptom Status: NYHA II-IVa
- •Treatment and compliance with optimal guideline directed medical therapy for heart failure for at least 1 month
- •Surgical risk: Subject is eligible for cardiac surgery
Exclusion Criteria
- •Patients with significant organic mitral valve pathology (e.g. myxomatous degeneration, mitral valve prolapse or flail leaflets)
- •Myocardial infarction or any percutaneous cardiovascular intervention, cardiovascular surgery, or carotid surgery within 30 days
- •Prior surgical, transcatheter, or percutaneous mitral valve intervention
- •Untreated clinically significant coronary artery disease requiring revascularization
- •Hemodynamic instability: Hypotension or requirement for inotropic support or mechanical hemodynamic support
- •Any planned cardiac surgery or interventions within the next 6 months
- •NYHA class IVb (i.e., non-ambulatory) or ACC/AHA Stage D heart failure
- •Fixed pulmonary artery systolic pressure >70 mmHg
- •Severe tricuspid regurgitation
- •Modified Rankin Scale ≥ 4 disability
- •Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or any other structural heart disease causing heart failure other than dilated cardiomyopathy of either ischemic or non-ischemic etiology
- •Mitral valve area less than 4.0 cm2
- •Anatomical pathology/constraints preventing appropriate access/implant of the GDS Accucinch System
- •Renal insufficiency
- •Mitral annular calcification
- •Moderate or severe aortic valve stenosis or regurgitation or aortic valve prosthesis
- •Fluoroscopic or echocardiographic evidence of severe aortic arch calcification, mobile aortic atheroma, intracardiac mass, thrombus or vegetation
- •Active bacterial endocarditis
- •History of stroke within the prior 3 months
- •Subjects in whom anticoagulation is contraindicated
- •Thrombocytopenia or thrombocytosis
- •Bleeding disorders or hypercoaguable state
- •Active peptic ulcer or active gastrointestinal bleeding
- •Known allergy to nitinol, polyester, or polyethylene
- •Any prior true anaphylactic reaction to contrast agents; defined as known anaphylactoid or other non-anaphylactic allergic reactions to contrast agents that cannot be adequately pre-medicated prior to the index procedure.
- •Life expectancy < 1 year due to non-cardiac conditions
- •Currently participating in another interventional investigational study
- •Implant or revision of any rhythm management device or implantable cardioverter defibrillator within the prior month
- •Absence of CRT with class I indication criteria for biventricular pacing - Subjects on high dose steroids or immunosuppressant therapy
- •Female subjects who are pregnant, of child bearing potential or lactating
Arms & Interventions
Accucinch Implant
Experimental
Accucinch Implant procedure is completed
Intervention: Accucinch Implant (Device)
Outcomes
Primary Outcomes
The additive reduction in the mitral annular axial dimensions (anteroposterior plus commissure-to-commissure axes) measured via echocardiography, paired by subject
Time Frame: 6 months
The differences between baseline and 6 months in the sum of the two annulus measures will be calculated for each subject and the mean change tested via the paired t-test.
Secondary Outcomes
- Device Success: Percentage of patients in whom all pre-specified device performance endpoints are met but no pre-specified device complications are met.(30 Days, 6 months, 12 months, and 2 years)
- Procedural Safety: Incidence rate of the occurrence of the individual pre-specified safety events that occur within 30 days of the index procedure(30 days after the index procedure)
- Long Term Safety: Incidence rate of the occurrence of the individual pre-specified safety events at 6 months, 1 year, and 2 years.(6 months, 1 year, 2 years post index procedure)
Investigators
Similar Trials
Active, not recruiting
Not Applicable
Evaluate the Safety and Performance of the AccuCinch® Ventricular Repair System - The CorCinch-EU StudyCardiomyopathiesHeart FailureNCT03183895Ancora Heart, Inc.132
Suspended
Not Applicable
Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF StudyDilated CardiomyopathyNCT04331769Ancora Heart, Inc.400
Completed
Not Applicable
Early Feasibility Study of the AccuCinch® Ventricular Restoration System in Patients With Prior Mitral Valve Intervention (PMVI) and Recurrent Mitral RegurgitationCardiomyopathy, DilatedHeart FailureNCT03560167Ancora Heart, Inc.5
Completed
Not Applicable
The CorCinch - Functional Mitral Valve Regurgitation (FMR) StudyMitral Valve InsufficiencyCardiomyopathiesHeart FailureNCT02806570Ancora Heart, Inc.35
Completed
Not Applicable
Sunstone IPL (Intense Pulsed Light) for Hair ReductionHair RemovalNCT03921814Philips Healthcare102